孕妇接种不同剂量重组含百日咳疫苗后母体抗体有效且安全地转移并持续至产后两个月
本研究为2019年一项2期试验的随访,400名孕妇在孕中期或孕晚期随机接种含1 µg PTgen和1 µg FHA的重组百日咳疫苗、与Td联合的疫苗或化学灭活对照疫苗。所有疫苗组母婴抗体转移比值均大于1,婴儿出生时PT抗体几何平均浓度均≥30 IU/mL,TdaP5gen组最高;产后2个月TdaP5gen组PT抗体几何平均浓度比值显著高于对照,各疫苗组不良事件相当。
要点
- 婴儿出生时与母亲分娩时抗PT和抗FHA抗体几何平均浓度比值在所有组均大于1。
- 所有组婴儿出生时PT抗体几何平均浓度均≥30 IU/mL,TdaP5gen组最高为118.8(95%CI 93.9-150.4)。
- 产后2个月TdaP5gen组PT抗体几何平均浓度比值较Tdap8chem组显著更高(2.6,98.75%CI 1.7-4.0)。
核心结论
- 孕妇在孕中期或孕晚期接种已获许可的TdaP5gen、Tdap2gen及候选疫苗Tdap1gen、ap1gen是安全的,并诱导了婴儿的被动百日咳免疫。
研究设计与样本
- 本研究为2019年一项2期试验的随访,400名孕妇随机接种一剂重组百日咳疫苗或化学灭活对照疫苗,接种时间为孕中期或孕晚期。
- 疫苗分组包括含1 µg PTgen和1 µg FHA的重组百日咳疫苗(ap1gen)、Td联合ap1gen(Tdap1gen)、Td联合2 µg PTgen和5 µg FHA(Tdap2gen)、Td联合5 µg PTgen和5 µg FHA(TdaP5gen,Boostagen®,BioNet,泰国)以及化学灭活对照疫苗(Tdap8chem,Boostrix™,GSK,比利时)。
- 采用ELISA检测抗PT、抗FHA、抗TT和抗DT的IgG,采用中国仓鼠卵巢细胞试验检测PT中和抗体(PTNA),并评估母亲分娩时和婴儿出生时的安全性结局。
主要发现
- 婴儿出生时与母亲分娩时抗PT和抗FHA抗体几何平均浓度比值在所有组均大于1。
- 所有组婴儿出生时PT抗体几何平均浓度均≥30 IU/mL,TdaP5gen组婴儿出生时滴度最高为118.8(95%CI 93.9-150.4)。
- 产后2个月,TdaP5gen组PT抗体几何平均浓度比值较Tdap8chem组显著更高(2.6,98.75%CI 1.7-4.0),其他重组疫苗与之相当。
- 所有组之间以及不同接种时间之间婴儿出生时PTNA滴度无差异。
- 所有疫苗组不良事件相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recombinant acellular pertussis (ap) vaccines containing genetically inactivated pertussis toxin (PTgen) and filamentous hemagglutinin (FHA) with or without tetanus (TT) and diphtheria (DT) vaccines (Td) were found safe and immunogenic in non-pregnant and pregnant women. We report here maternal antibody transfer and safety data in mothers and neonates. METHODS: This is the follow up of a phase 2 trial in 2019 among 400 pregnant women who randomly received one dose of recombinant pertussis-only vaccine containing 1 µg PTgen and 1 µg FHA (ap1gen), or Td combined with ap1gen (Tdap1gen), or with 2 µg PTgen and 5 µg FHA (Tdap2gen), or with 5 µg PTgen and 5 µg FHA (TdaP5gen, Boostagen®, BioNet, Thailand) or chemically-inactivated acellular pertussis comparator (Tdap8chem, Boostrix™, GSK, Belgium), either in the second or third trimester of gestation. IgG against PT, FHA, TT and DT were assessed by ELISA, PT-neutralizing antibodies (PTNA) by Chinese Hamster Ovary cell assay and safety outcomes at delivery in mothers and at birth. RESULTS: Anti-PT and anti-FHA geometric mean concentration (GMC) ratio between infants at birth and mothers at delivery was above 1 in all groups. PT GMC in infants at birth were ≥30 IU/mL in all groups with the highest titers in infants found in TdaP5gen group at birth (118.8 [95% CI 93.9-150.4]). At 2 months, PT GMC ratio to Tdap8chem (98.75% CI) was significantly higher for TdaP5gen (2.6 [1.7-4.0]) and comparable for other recombinant vaccines. No difference in PTNA titers at birth was observed between all groups nor between time of vaccination. Adverse events were comparable in all vaccine groups. CONCLUSIONS: BioNet licensed (TdaP5gen and Tdap2gen) and candidate vaccines (Tdap1gen and ap1gen) when given to pregnant women in the second or third trimester of gestation are safe and have induced passive pertussis immunity to infants.
引用
- Chokephaibulkit K, Puthanakit T, Chaithongwongwatthana S, et al. Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines. Vaccine. 2023. PMID: 38061956. doi:10.1016/j.vaccine.2023.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。